Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 1
2022 4
2023 9
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
Drexler R, Göttsche J, Sauvigny T, Schüller U, Khatri R, Hausmann F, Hänzelmann S, Huber TB, Bonn S, Heiland DH, Delev D, Venkataramani V, Winkler F, Weller J, Zeyen T, Herrlinger U, Gempt J, Ricklefs FL, Dührsen L. Drexler R, et al. Among authors: zeyen t. Neuro Oncol. 2023 May 4;25(5):1006-1008. doi: 10.1093/neuonc/noad014. Neuro Oncol. 2023. PMID: 36860191 Free PMC article. No abstract available.
Five-Fraction Stereotactic Radiotherapy for Brain Metastases-A Retrospective Analysis.
Layer JP, Layer K, Sarria GR, Röhner F, Dejonckheere CS, Friker LL, Zeyen T, Koch D, Scafa D, Leitzen C, Köksal M, Schmeel FC, Schäfer N, Landsberg J, Hölzel M, Herrlinger U, Schneider M, Giordano FA, Schmeel LC. Layer JP, et al. Among authors: zeyen t. Curr Oncol. 2023 Jan 17;30(2):1300-1313. doi: 10.3390/curroncol30020101. Curr Oncol. 2023. PMID: 36826062 Free PMC article.
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. J Neurooncol. 2023 Sep;164(3):607-616. doi: 10.1007/s11060-023-04444-x. Epub 2023 Sep 20. J Neurooncol. 2023. PMID: 37728779 Free PMC article.
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Weller J, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Schlegel U, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Pietsch T, Tzaridis T, Zeyen T, Borger V, Güresir E, Vatter H, Herrlinger U, Schneider M. Weller J, et al. Among authors: zeyen t. J Neurooncol. 2022 Aug;159(1):95-101. doi: 10.1007/s11060-022-04046-z. Epub 2022 Jun 15. J Neurooncol. 2022. PMID: 35704157 Free PMC article. Clinical Trial.
Impact of the SARS-CoV-2 pandemic on the survival of patients with high-grade glioma and best practice recommendations.
Vogel MME, Wagner A, Gempt J, Krenzlin H, Zeyen T, Drexler R, Voss M, Nettekoven C, Abboud T, Mielke D, Rohde V, Timmer M, Goldbrunner R, Steinbach JP, Dührsen L, Westphal M, Herrlinger U, Ringel F, Meyer B, Combs SE. Vogel MME, et al. Among authors: zeyen t. Sci Rep. 2023 Feb 16;13(1):2766. doi: 10.1038/s41598-023-29790-8. Sci Rep. 2023. PMID: 36797335 Free PMC article.
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Zeyen T, Potthoff AL, Nemeth R, Heiland DH, Burger MC, Steinbach JP, Hau P, Tabatabai G, Glas M, Schlegel U, Grauer O, Krex D, Schnell O, Goldbrunner R, Sabel M, Thon N, Delev D, Clusmann H, Seidel C, Güresir E, Schmid M, Schuss P, Giordano FA, Radbruch A, Becker A, Weller J, Schaub C, Vatter H, Schilling J, Winkler F, Herrlinger U, Schneider M. Zeyen T, et al. Trials. 2022 Jan 19;23(1):57. doi: 10.1186/s13063-021-05977-0. Trials. 2022. PMID: 35045869 Free PMC article. Clinical Trial.
Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. J Neurooncol. 2023 Nov;165(2):387. doi: 10.1007/s11060-023-04488-z. J Neurooncol. 2023. PMID: 37921974 Free PMC article. No abstract available.
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
Weller J, Zeyen T, Schäfer N, Schaub C, Potthoff AL, Steinbach JP, Hau P, Seidel C, Goldbrunner R, Tabatabai G, Vatter H, Tzaridis T, Schneider M, Herrlinger U. Weller J, et al. Among authors: zeyen t. J Neurooncol. 2023 Sep;164(3):749-755. doi: 10.1007/s11060-023-04470-9. Epub 2023 Oct 3. J Neurooncol. 2023. PMID: 37787906 Free PMC article.
16 results